The trial selected an aggregate of 519 patients crosswise over 35 focuses in the United States. All rights reserved.
[ September 10, 2020 ] The company traded as low as $0.87 and last traded at $0.89. Financial specialists ought to note that outcomes for this trial could take 2 to 3 years. Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. In another most recent transaction, which held on 6/30/2020, BRIDGEWAY CAPITAL MANAGEMENT, IN bought approximately 264.5 thousand shares of Tonix Pharmaceuticals … The stock remained 11.97% volatile for the week and 12.12% for the month. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. Separately, Alliance Global Partners increased their target price on shares of Tonix Pharmaceuticals from $2.50 to $3.00 in a research note on Thursday, August 20th.The firm’s 50 day moving average is $1.05 and its 200 day moving average is $0.79. Rio Tinto CEO resigns over destruction of caves The stock remained 10.37% volatile for the week and 12.56% for the month. Shares of Tonix Pharmaceuticals reverse split before market open on Wednesday, November 28th 2018.
Hence, it is judicious to consider holding long for those hoping to purchase Tonix offers for this stage 3 trial. The institutional investor purchased 62,008 shares of the company’s stock, valued at approximately $38,000. Specifically, they have bought $89,879.00 in company stock and sold $0.00 in company stock.Only 0.15% of the stock of Tonix Pharmaceuticals is held by insiders.Only 1.13% of the stock of Tonix Pharmaceuticals is held by institutions.Earnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($0.59) to ($0.37) per share.The P/E ratio of Tonix Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of Tonix Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Tonix Pharmaceuticals has a P/B Ratio of 0.69. Want to see which stocks are moving? * Tonix Pharmaceuticals Holding Corp (TNXP) - SALE AGREEMENT FOR 20.9 MILLION SHARES AT AN OFFERING PRICE OF $0.50 PER SHARE Source text for Eikon: Further company coverage: Manage a group of micro-cap investors on Facebook with over 15,000 members.
Been writing about and trading stocks since 2013. Tonix Pharmaceuticals Holding Corp . Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock.
"Tonix Pharmaceuticals' stock is owned by a variety of retail and institutional investors. [ September 10, 2020 ] 3 Active Stocks Watch List: Senior Housing Properties (NYSE:SNH), Basic Energy Services (NYSE:BAS), Verisign (NASDAQ:VRSN) The length of the study was to survey a 12-week treatment period in which patients would be assessed for their Fibromyalgia. TNXP 0.83 0.05 (5.60%). Tonix Pharmaceuticals started at buy with $8 stock price target at B. Riley FBRTonix Pharmaceuticals' stock plunges 18% premarket after stock offering announced late Wednesday That is a major bet, in light of the fact that on the off chance that this last trial comes up short the organization will have nothing of significant worth left.